142 related articles for article (PubMed ID: 24862330)
1. Modeling and simulation approach to support dosing and study design requirements for treating HIV-related neuropsychiatric disease with the NK1-R antagonist aprepitant.
Barrett JS; Bajaj G; McGuire J; Wu D; Spitsin S; Moorthy G; Zhao X; Tebas P; Evans DL; Douglas SD
Curr HIV Res; 2014; 12(2):121-31. PubMed ID: 24862330
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV.
Barrett JS; Spitsin S; Moorthy G; Barrett K; Baker K; Lackner A; Tulic F; Winters A; Evans DL; Douglas SD
J Transl Med; 2016 May; 14(1):148. PubMed ID: 27230663
[TBL] [Abstract][Full Text] [Related]
3. Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults.
Tebas P; Spitsin S; Barrett JS; Tuluc F; Elci O; Korelitz JJ; Wagner W; Winters A; Kim D; Catalano R; Evans DL; Douglas SD
AIDS; 2015 May; 29(8):931-9. PubMed ID: 25915168
[TBL] [Abstract][Full Text] [Related]
4. NK1 receptor antagonists for depression: Why a validated concept was abandoned.
Rupniak NMJ; Kramer MS
J Affect Disord; 2017 Dec; 223():121-125. PubMed ID: 28753469
[TBL] [Abstract][Full Text] [Related]
5. A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults.
Tebas P; Tuluc F; Barrett JS; Wagner W; Kim D; Zhao H; Gonin R; Korelitz J; Douglas SD
PLoS One; 2011; 6(9):e24180. PubMed ID: 21931661
[TBL] [Abstract][Full Text] [Related]
6. Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals.
Manak MM; Moshkoff DA; Nguyen LT; Meshki J; Tebas P; Tuluc F; Douglas SD
AIDS; 2010 Nov; 24(18):2789-96. PubMed ID: 20975512
[TBL] [Abstract][Full Text] [Related]
7. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
8. The NK1 receptor antagonist aprepitant attenuates NK1 agonist-induced scratching behaviour in the gerbil after intra-dermal, topical or oral administration.
Costantini VJ; Corsi M; Dünstl G; Bettelini L; Zonzini L; Gerrard P
Exp Dermatol; 2015 Apr; 24(4):312-4. PubMed ID: 25650546
[TBL] [Abstract][Full Text] [Related]
9. Neurokinin-1 receptor inhibition reverses ischaemic brain injury and dementia in bilateral common carotid artery occluded rats: possible mechanisms.
Kaur J; Sharma S; Sandhu M; Sharma S
Inflammopharmacology; 2016 Aug; 24(4):133-43. PubMed ID: 27380492
[TBL] [Abstract][Full Text] [Related]
10. Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant.
Ohanyan T; Schoepke N; Eirefelt S; Hoey G; Koopmann W; Hawro T; Maurer M; Metz M
Acta Derm Venereol; 2018 Jan; 98(1):26-31. PubMed ID: 28853492
[TBL] [Abstract][Full Text] [Related]
11. Opioid-like effects of the neurokinin 1 antagonist aprepitant in patients maintained on and briefly withdrawn from methadone.
Jones JD; Speer T; Comer SD; Ross S; Rotrosen J; Reid MS
Am J Drug Alcohol Abuse; 2013 Mar; 39(2):86-91. PubMed ID: 23421568
[TBL] [Abstract][Full Text] [Related]
12. The neurokinin-1 receptor antagonist aprepitant in co-morbid alcohol dependence and posttraumatic stress disorder: a human experimental study.
Kwako LE; George DT; Schwandt ML; Spagnolo PA; Momenan R; Hommer DW; Diamond CA; Sinha R; Shaham Y; Heilig M
Psychopharmacology (Berl); 2015 Jan; 232(1):295-304. PubMed ID: 25030801
[TBL] [Abstract][Full Text] [Related]
13. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant.
Bergström M; Hargreaves RJ; Burns HD; Goldberg MR; Sciberras D; Reines SA; Petty KJ; Ogren M; Antoni G; Långström B; Eskola O; Scheinin M; Solin O; Majumdar AK; Constanzer ML; Battisti WP; Bradstreet TE; Gargano C; Hietala J
Biol Psychiatry; 2004 May; 55(10):1007-12. PubMed ID: 15121485
[TBL] [Abstract][Full Text] [Related]
14. Effects of NK1 receptors on gastric motor functions and satiation in healthy humans: results from a controlled trial with the NK1 antagonist aprepitant.
Jacob D; Busciglio I; Burton D; Halawi H; Oduyebo I; Rhoten D; Ryks M; Harmsen WS; Camilleri M
Am J Physiol Gastrointest Liver Physiol; 2017 Nov; 313(5):G505-G510. PubMed ID: 28814387
[TBL] [Abstract][Full Text] [Related]
15. The neurokinin1 receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy.
Warr D
Expert Opin Pharmacother; 2006 Aug; 7(12):1653-8. PubMed ID: 16872268
[TBL] [Abstract][Full Text] [Related]
16. Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging.
Van Laere K; De Hoon J; Bormans G; Koole M; Derdelinckx I; De Lepeleire I; Declercq R; Sanabria Bohorquez SM; Hamill T; Mozley PD; Tatosian D; Xie W; Liu Y; Liu F; Zappacosta P; Mahon C; Butterfield KL; Rosen LB; Murphy MG; Hargreaves RJ; Wagner JA; Shadle CR
Clin Pharmacol Ther; 2012 Aug; 92(2):243-50. PubMed ID: 22739139
[TBL] [Abstract][Full Text] [Related]
17. Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioral effects of NK1 antagonists.
Duffy RA; Varty GB; Morgan CA; Lachowicz JE
J Pharmacol Exp Ther; 2002 May; 301(2):536-42. PubMed ID: 11961054
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts.
Muñoz M; Berger M; Rosso M; Gonzalez-Ortega A; Carranza A; Coveñas R
Int J Oncol; 2014 Jan; 44(1):137-46. PubMed ID: 24190675
[TBL] [Abstract][Full Text] [Related]
19. Effect of aprepitant on kynurenine to tryptophan ratio in cART treated and cART naïve adults living with HIV.
Spitsin S; Pappa V; Kinder A; Evans DL; Rappaport J; Douglas SD
Medicine (Baltimore); 2021 Jun; 100(23):e25313. PubMed ID: 34114978
[TBL] [Abstract][Full Text] [Related]
20. Placebo- and amitriptyline-controlled evaluation of central nervous system effects of the NK1 receptor antagonist aprepitant and intravenous alcohol infusion at pseudo-steady state.
te Beek ET; Tatosian D; Majumdar A; Selverian D; Klaassen ES; Petty KJ; Gargano C; van Dyck K; McCrea J; Murphy G; van Gerven JM
J Clin Pharmacol; 2013 Aug; 53(8):846-56. PubMed ID: 23775877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
